US Patent Issued to Boostimmune, THE UNIVERSITY OF TOKYO on June 17 for "Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer" (South Korean, Japanese Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,329,814, issued on June 17, was assigned to Boostimmune Inc. (Seoul, South Korea) and THE UNIVERSITY OF TOKYO (Tokyo).

"Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer" was invented by Gwanghee Lee (Busan, South Korea), Jeonghyun Ryou (Gyeonggi-do, South Korea), Jiwon Huh (Seoul, South Korea), Tadatsugu Taniguchi (Tokyo), Sho Hangai (Tokyo) and Hideyuki Yanai (Tokyo).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a novel combination of (1) a substance that suppresses or inhibits the function of extracellular TCTP (translationally controlled tumor protein), ...